Several targets undergoing investigation for NSCLC CARs include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen (CEA), mesothelin (MSLN), prostate stem cell antigen (PSCA), mucin 1 (MUC1), tyrosine kinase-like orphan receptor 1 (ROR1), and programmed death ligand 1 (PD-L1) among others. This evidence concerns the gene ROR1 and non-small cell lung carcinoma.